Article
Vice President Marianne Cunnington Elected to ISPE Board
Analysis Group congratulates Vice President Marianne Cunnington on her election to the Board of the International Society for Pharmacoepidemiology (ISPE) as the representative for industry and service providers in Europe and Africa. ISPE is an international organization that provides a scientific forum for the advancement of pharmacoepidemiology and its role in optimizing drug development and furthering the understanding of drug effects.
Dr. Cunnington has two decades of experience as an industry epidemiologist, generating regulatory grade real-world evidence (RWE) using pharmacoepidemiology methods in support of all stages of drug development. Her election to the Board is an opportunity for Dr. Cunnington to work with her colleagues to promote ISPE’s dedication to robust methods for and innovative approaches to the use of RWE in drug development.
Meet Our People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and life cycle management of pharmaceutical and vaccine products, with a particular focus on regulatory risk management strategies and product benefit-risk assessments. Dr. Cunnington’s research expertise includes the design, negotiation, and execution of real-world components of risk management plans for new product submission to regulators in the US, UK, EU, Japan, and South Korea, including studies of post-approval safety in the EU; post-marketing requirements and commitments in the US; and pregnancy registries. Prior to joining Analysis Group, she served in several senior epidemiology positions at pharmaceutical companies, including as the chair of GSK’s peer review forum for all pharmaceutical RWE projects; as a member of GSK’s Global Safety Board; as head of epidemiology at Novartis Vaccines; and as a managing board member of Innovative Medicines’ public-private partnership initiative to build an integrated European real-world data (RWD) network to monitor medication safety in pregnancy.